A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis

Arthritis and Rheumatism

Volumn 56, Issue 4, 2007, Pages 1164-1174

  Saito, Hiroaki ^a,b   Kojima, Takefumi ^a   Takahashi, Mariko ^a   Horne, William C ^b   Baron, Roland ^b   Amagasa, Teruo ^a   Ohya, Keiichi ^a   Aoki, Kazuhiro ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CYCLOPEPTIDE; INFLIXIMAB; TYROSYLCYSTEINYLTRYPTOPHYLSERYLGLUTAMINYLTYROSYLLEUCYLCYSTEINYLTYROSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; CELL COUNT; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; HISTOPATHOLOGY; JOINT DESTRUCTION; JOINT RADIOGRAPHY; MALE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; OSTEOCLAST; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ABSTRACTING AND INDEXING; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, EXPERIMENTAL; BONE RESORPTION; DOSE-RESPONSE RELATIONSHIP, DRUG; HINDLIMB; JOINTS; MALE; MICE; MICE, INBRED DBA; OSTEOCLASTS; PEPTIDES, CYCLIC; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34247279368     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22495     Document Type: Article

References (36)

1. Chen E, Keystone EC, Fish EN. Restricted cytokine expression in rheumatoid arthritis. Arthritis Rheum 1993;36:901-10.
2. Pincus T. Long-term outcomes in rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl 2:59-73.
3. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
4. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7.
5. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
6. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
7. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fix RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
8. Zhang X, Piatier-Tonneau D, Auffray C, Murali R, Mahapatra A, Zhang F, et al. Synthetic CD4 exocyclic peptides antagonize CD4 holoreceptor binding and T cell activation. Nat Biotechnol 1996;14:472-5.
9. Zhang X, Gaubin M, Briant L, Srikantan V, Murali R, Saragovi U, et al. Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes. Nat Biotechnol 1997;15:150-4.
10. Takasaki W, Kajino Y, Kajino K, Murali R, Greene MI. Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF α binding to its receptor. Nat Biotechnol 1997;15:1266-70.
11. Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF β complex: implications for TNF receptor activation. Cell 1993;73:431-45.
12. Eck MJ, Sprang SR. The structure of tumor necrosis factor-α at 2.6 Å resolution: implications for receptor binding. J Biol Chem 1989;264:17595-605.
13. Iwai H, Kozono Y, Hirose S, Akiba H, Yagita H, Okumura K, et al. Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation. J Immunol 2002;169:4332-9.
14. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992;89:9784-8.
15. Tsurukami H, Nakamura T, Suzuki K, Sato K, Higuchi Y, Nishii Y. A novel synthetic vitamin D analogue, 2 β-(3-hydroxypropoxy)1 α, 25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif Tissue Int 1994;54:142-9.
16. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999;42:498-506.
17. Seto H, Aoki K, Kasugai S, Ohya K. Trabecular bone turnover, bone marrow cell development, and gene expression of bone matrix proteins after low calcium feeding in rats. Bone 1999;25:687-95.
18. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987;2:595-610.
19. v mutant mice. Bone 1999;25:261-7.
20. Nishida S, Tsurukami H, Sakai A, Sakata T, Ikeda S, Tanaka M, et al. Stage-dependent changes in trabecular bone turnover and osteogenic capacity of marrow cells during development of type II collagen-induced arthritis in mice. Bone 2002;30:872-9.
21. Tanaka S, Nakamura K, Takahasi N, Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 2005;208:30-49.
22. Feldmann M. The cytokine network in rheumatoid arthritis: definition of TNF α as a therapeutic target. J R Coll Physicians Lond 1996;30:560-70.
23. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
24. Jones G, Halbert J, Crotty M, Shanahan EM, Batterham M, Ahern M. The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. Rheumatology (Oxford) 2003;42:6-13.
25. Fujikawa Y, Shingu M, Torisu T, Itonaga I, Masumi S. Bone resorption by tartrate-resistant acid phosphatase-positive multinuclear cells isolated from rheumatoid synovium. Br J Rheumatol 1996;35:213-7.
26. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996;11:88-95.
27. Takayanagi H, Oda H, Yamamoto S, Kawaguchi H, Tanaka S, Nishikawa T, et al. A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. Biochem Biophys Res Commun 1997;240:279-86.
28. Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002;161:1419-27.
29. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-99.
30. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000;275:4858-64.
31. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, et al. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000;191:275-86.
32. Redlich K, Gortz B, Hayer S, Zwerina J, Doerr N, Kostenuik P, et al. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol 2004;164:543-55.
33. Saidenberg-Kermanac'h N, Corrado A, Lemeiter D, deVernejoul MC, Boissier MC, Cohen-Solal ME. TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 2004;35:1200-7.
34. Aoki K, Saito H, Itzstein C, Ishiguro M, Shibata T, Blanque R, et al. TNF-α receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. J Clin Invest 2006;116:1525-34.
35. Kojima T, Aoki K, Nonaka K, Saito H, Azuma M, Iwai H, et al. Subcutaneous injections of a TNF-α antagonistic peptide inhibit both inflammation and bone resorption in collagen-induced murine arthritis. J Med Dent Sci 2005;52:91-9.
36. Deng GM, Zheng L, Chan FK, Leonardo M. Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. Nat Med 2005;10:1066-72.